People with parkinsonism have a much higher risk of hip and other fractures. Our friends at UCSF and other US clinics are recruiting for the TOPAZ (Trial of Parkinson’s and Zoledronic Acid) study. Researchers will test if zoledronate, an FDA-approved medication for osteoporosis (thinning of the bone), can prevent fractures in people with parkinsonism, whether or not they have osteoporosis.
Using zoledronate for this purpose is investigational.
Enroll today! Participate in the TOPAZ study remotely, from the comfort of your home. You could receive $100 upon enrollment and $50 per year during the study.
To be eligible, individuals must be at least 60 years of age with NO prior hip fracture, AND have been diagnosed with any of the following conditions:
- Parkinson’s disease
- Dementia with Lewy bodies
- Multiple system atrophy
- Progressive supranuclear palsy
- Cortical basal degeneration
- Vascular parkinsonism
- or another form of neurodegenerative parkinsonism
To learn more or to enroll, visit the study website TOPAZstudy.org. If you have questions, email [email protected], or call 415-317-5748.
The most recent issue of “Expert Review of Neurotherapeutics” includes a review article on the treatment of hallucinations in Parkinson’s disease. Of course this applies to Lewy body dementia as well. 
